Stock Traders Purchase Large Volume of Exelixis Put Options (EXEL)
Exelixis, Inc. (NASDAQ:EXEL) was the target of unusually large options trading on Monday. Stock traders acquired 5,591 put options on the stock. This represents an increase of approximately 1,727% compared to the typical volume of 306 put options.
In other news, insider Michael Morrissey sold 234,267 shares of the stock in a transaction that occurred on Thursday, August 9th. The stock was sold at an average price of $21.04, for a total value of $4,928,977.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Vincent T. Marchesi sold 40,000 shares of the stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $19.50, for a total value of $780,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 586,129 shares of company stock valued at $11,655,453. Company insiders own 4.80% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. James Investment Research Inc. bought a new position in Exelixis during the 2nd quarter valued at approximately $133,000. TLP Group LLC bought a new stake in shares of Exelixis in the 1st quarter worth $179,000. Washington Trust Bank bought a new stake in shares of Exelixis in the 2nd quarter worth $213,000. Oppenheimer Asset Management Inc. bought a new stake in shares of Exelixis in the 2nd quarter worth $217,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of Exelixis in the 3rd quarter worth $183,000. 80.90% of the stock is owned by institutional investors.
EXEL stock opened at $15.90 on Tuesday. Exelixis has a twelve month low of $15.49 and a twelve month high of $32.50. The company has a market cap of $5.28 billion, a P/E ratio of 31.18 and a beta of 1.94.
Exelixis (NASDAQ:EXEL) last posted its quarterly earnings data on Wednesday, August 1st. The biotechnology company reported $0.28 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.16 by $0.12. Exelixis had a return on equity of 65.68% and a net margin of 48.17%. The company had revenue of $186.10 million during the quarter, compared to analyst estimates of $157.37 million. During the same quarter last year, the company earned $0.06 EPS. The firm’s revenue for the quarter was up 88.0% on a year-over-year basis. On average, equities analysts forecast that Exelixis will post 1.03 earnings per share for the current year.
Exelixis Company Profile
Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.
Featured Article: Ex-Dividend
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.